Extended Data Fig. 1: ctDNA status in the MRD window is predictive of DFS across all stages in postsurgical patients with CRC.
From: ctDNA-based molecular residual disease and survival in resectable colorectal cancer
a-f. Kaplan-Meier estimates for DFS stratified by ctDNA status during the MRD window (negative versus positive) in patients with pathologic stage I (a), stage II (b), stage III (c), stage IV (d), high-risk stage II (e), and high-risk stage III (f) CRC. P = 1.66 × 10−5 (a); P = 1.05 × 10−33 (b); P = 9.55 × 10−59 (c); P = 3.82 × 10−37 (d); P = 8.30 × 10−30 (e); P = 9.66 × 10−36 (f). Hazard ratios (HRs) and 95% CIs were calculated using the Cox proportional hazard model. P values were calculated using the two-sided log-rank test. This analysis was landmarked from the date of the MRD time point. Median DFS and percent DFS at 24 months were estimated from the landmark time point. Abbreviations: MRD, molecular residual disease. DFS, disease-free survival.
